Anaconda Biomed, a medical device company focused on the development of the next generation of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS) located in Barcelona, announces it has closed a series A financing of €15-million. The leading investors include Ysios Capital, Omega Funds, Banco Sabadell as well as current investor Innogest Capital.

Dr Ofir Arad, co-Founder and CEO of Anaconda Biomed, explains this financing "provide us the capital necessary to substantially progress the development of the ANCD Brain device, including the validation and verification process, clinical studies to support the initial commercialization in Europe, and an initial submission to FDA".  

"Is a great news for the consolidation of the medtech ecosystem in Barcelona but also for the amazing work of the founders in putting together a disruptive medical device by combining excellent medicine with high tech chemistry" said Josep Lluís Sanfeliu, partner at Ysios Capital.

More information on Ysios Capital website.

Photo: Dr Ofir Arad and Dr Marc Ribó, co-Founders of Anaconda Biomed - © Anaconda Biomed